Slow Capital Inc. Makes New $4.38 Million Investment in BeOne Medicines Ltd. – Sponsored ADR $ONC

Slow Capital Inc. bought a new stake in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) during the 2nd quarter, Holdings Channel reports. The firm bought 18,083 shares of the company’s stock, valued at approximately $4,377,000.

A number of other large investors have also recently made changes to their positions in the stock. Public Employees Retirement System of Ohio purchased a new position in shares of BeOne Medicines in the 2nd quarter worth $3,491,000. Mirae Asset Global Investments Co. Ltd. purchased a new position in BeOne Medicines in the second quarter worth about $926,000. Perigon Wealth Management LLC bought a new stake in shares of BeOne Medicines during the 2nd quarter valued at about $581,000. Janney Montgomery Scott LLC purchased a new stake in shares of BeOne Medicines during the 2nd quarter valued at about $373,000. Finally, QRG Capital Management Inc. bought a new position in shares of BeOne Medicines in the 2nd quarter worth approximately $367,000. 48.55% of the stock is currently owned by institutional investors.

BeOne Medicines Trading Up 0.2%

Shares of ONC stock opened at $344.53 on Tuesday. The company has a market cap of $37.76 billion, a PE ratio of -199.15 and a beta of 0.31. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $170.99 and a 1 year high of $355.30. The stock’s 50 day simple moving average is $319.57 and its two-hundred day simple moving average is $274.54. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.95 and a quick ratio of 1.72.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.36. The company had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.24 billion. BeOne Medicines had a negative return on equity of 1.22% and a negative net margin of 3.89%. Research analysts predict that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 earnings per share for the current year.

Insider Activity at BeOne Medicines

In related news, Director Corazon (Corsee) D. Sanders sold 2,665 shares of BeOne Medicines stock in a transaction that occurred on Friday, September 5th. The shares were sold at an average price of $337.00, for a total value of $898,105.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Lai Wang sold 5,000 shares of the firm’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $350.06, for a total value of $1,750,300.00. The disclosure for this sale can be found here. Insiders have sold 181,315 shares of company stock valued at $54,839,498 over the last 90 days. Insiders own 6.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a research report on Saturday, September 27th. Barclays started coverage on BeOne Medicines in a research note on Thursday, September 18th. They issued an “overweight” rating and a $385.00 price objective for the company. Royal Bank Of Canada lifted their target price on BeOne Medicines from $349.00 to $364.00 and gave the company an “outperform” rating in a research report on Thursday, August 7th. JPMorgan Chase & Co. raised their price objective on BeOne Medicines from $321.00 to $345.00 and gave the stock an “overweight” rating in a research note on Thursday, July 17th. Finally, Zacks Research upgraded BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $336.30.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.